Salutary attributes of probiotic human gut lactobacilli for gut health.

Lactobacilli are GRAS organisms and are important members of gut microbiota. They have been strongly recommended as probiotics because of many benefits provided by them to overall human health. Human gut lactobacilli with salutary properties can provide additional advantages. Limosilactobacillus fermentumL1 MW600457, L. fermentumL3 MW600480, L. fermentumL4 MW600464, L. fermentumL5 MW600493, L. fermentumL6 MW600495, L. fermentumL7 MW600496, L. fermentumL8 MW485761, Lactiplantibacillus plantarumL9 MW485746, and Ligilactobacillus salivariusL10 MW600498 with in vitro probiotic properties were explored for salutogenic characteristics. Salutary properties like ß-galactosidase activity, anthelminthic property assay, anti-inflammatory assay, antidiabetic study, cholesterol assimilation assay, and biofilm assay were performed. All the isolates were positive for ß-galactosidase activity. The anthelminthic property with minimum paralysis time and death time between 16-25 min was shown by L.fermentumL8 MW485761. Anti-inflammatory activity with bovine serum albumin was maximum at 200 µg ml-1 concentration. α-amylase inhibitory activity was maximum for L. fermentumL8 MW485761 (51%). Maximum cholesterol assimilation was reported for L. fermentumL6 MW600495 (76%). Strong biofilm forming ability for all isolates improved the colonization and stability as probiotics. Human gut lactobacilli with salutary properties can make an efficient probiotic.

Antibacterial and antibiofilm activity of human gut lactic acid bacteria.

The present study focused on the antibacterial and antibiofilm activity of novel lactic acid bacterial (LAB) strains isolated from the healthy human volunteers of different age groups and their consortium (LABCON), against the enteropathogenic bacteria. From the study, methanolic extract of LAB isolates and their consortia were found to have promising antibacterial activity and antibiofilm activity against Escherichia coli (ATCC 35218) and Staphylococcus aureus (ATCC 25923). The antimicrobial compounds including the DL-3 phenyllactic acid, DL-p-hydroxyphenyllactic acid, and Succinic acid produced by the LAB could be considered to inhibit the growth and biofilm formation by E. coli (ATCC 35218) and S. aureus (ATCC 25923). Detailed insight into the antibiofilm activity could also be demonstrated by Confocal Raman microscopy attached with AFM and Fluorescent microscope. From the results of the study, the consortium LABCON was superior in antimicrobial and antibiofilm activity and can be considered to have promising application in infection control.